Patent US4767751A successfully refreshed from Google Patents.
US4767751A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Topical drug release system
Assignee: Beecham Group PLC
•
Filing: 1985-01-23
•
Granted: 1988-08-30
•
Expires: 2005-01-23
Abstract
Abstract A pharmaceutical composition for topical administration consisting of two liquid phases designed to be admixed in situ or prior to use. The first phase contains a dissolved drug, and is preferably saturated in the drug, while the second phase is a chemically or physically different liquid from that in the first phase and contains no drug, but is miscible with the first phase. The two liquids are selected so that, on admixture of suitable volumes of the phases, the resultant drug concentration exceeds the saturated drug solubility in the resultant mixture. This produces a liquid mixture supersaturated in drug, which has been found to increase the rate of drug penetration into the skin. The two liquid phases may be gels, and the drug may be hydrocortisone.
Inventors
- 👤 Adrian F. Davis
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 16:41
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/06
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
101 words
A pharmaceutical composition for topical application, comprising a first liquid phase and a second liquid phase different from the first phase but miscible with the first phase upon admixture therewith, at least one of said phases comprising a drug dissolved therein, the concentration of said drug in each phase in which said drug is present and the composition of the phases being such that, on admixture of the phases, the total drug concentration in the initially formed resultant mixture is greater than the saturated drug solubility in said initially formed resultant mixture, whereby said resultant mixture is supersaturated with the drug.
Claim 2
Dependent Claim
101 words
A pharmaceutical composition for topical application, comprising a first liquid phase and a second liquid phase different from the first phase but miscible with the first phase upon admixture therewith, at least one of said phases comprising a drug dissolved therein, the concentration of said drug in each phase in which said drug is present and the composition of the phases being such that, on admixture of the phases, the total drug concentration in the initially formed resultant mixture is greater than the saturated drug solubility in said initially formed resultant mixture, whereby said resultant mixture is supersaturated with the drug.
Claim 3
Dependent Claim
23 words
A composition according to claim 1, in which the first phase comprises a solubiliser, and the second phase comprises a pharmaceutically acceptable carrier.
Claim 4
Dependent Claim
30 words
A composition according to claim 2, in which the first phase comprises a mixture of a pharmaceutically acceptable carrier and said solubiliser, and the second phase comprises the same carrier.
Claim 5
Dependent Claim
40 words
A composition according to claim 1, in which the first phase comprises up to 50% of carrier, and from 50 to 100% of solubiliser, and the second phase comprises up to 50% solubiliser, and from 50 to 100% of carrier.
Claim 6
Dependent Claim
42 words
A composition according to claim 2, in which the solubiliser is propylene glycol, 1,3-propylene diol, polyethylene glycol, ethanol, propanol, glycerine, dimethyl sulphoxide, dimethyl acetamide, dimethylformamide, higher alcohol, higher carboxylic acid, fatty ester, mineral oil, vegetable oil, aqueous acid or an alkali buffer.
Claim 7
Dependent Claim
24 words
A composition according to claim 1 in which the drug is initially saturated in the first phase and is absent from the second phase.
Claim 8
Dependent Claim
31 words
A composition according to claim 1 in which the ratio of supersaturated drug concentration in said resultant mixture to saturated drug concentration in said resultant mixture is from 2:1 to 50:1.
Claim 9
Dependent Claim
17 words
A composition according to claim 1, in which the drug is hydrocortisone, ibuprofen, lignocaine, triclosan or glycine.
Claim 10
Dependent Claim
29 words
A twin compartment pack containing a composition according to claim 1, the first liquid phase being in one compartment and the second liquid phase being in the other compartment.
Claim 11
Dependent Claim
10 words
A transdermal device containing a composition according to claim 1.
Claim 12
Dependent Claim
20 words
A composition according to claim 3, in which said second phase comprises a mixture of said carrier and a solubiliser.
Claim 13
Dependent Claim
38 words
A composition according to claim 11, in which said second phase comprises a solubiliser which is the same as the solubiliser in the first phase but in a different weight ratio of carrier:solubiliser than in the first phase.
Claim 14
Dependent Claim
16 words
A composition according to claim 1, wherein said second phase also contains said drug dissolved therein.
Claim 15
Dependent Claim
33 words
A method for topical application of the pharmaceutical composition of claim 1, which comprises mixing said liquid phases to form a mixture supersaturated with said drug, and applying said mixture to the skin.
Claim 16
Dependent Claim
37 words
A method for topical application of the pharmaceutical composition of claim 1, which comprises applying said liquid phases to the skin and admixing said liquid phases to form on the skin a mixture supersaturated with said drug.
Claim 17
Dependent Claim
45 words
A method for topical application of the pharmaceutical composition contained in the twin-compartment pack of claim 9, which comprises mixing said liquid phases within said pack to form therein a mixture supersaturated with said drug and dispensing said mixture from said pack to the skin.
Claim 18
Dependent Claim
45 words
A method for the topical administration of the pharmaceutical composition contained in the transdermal device of claim 10, which comprises mixing said liquid phases within said device to form therein a mixture supersaturated with said drug, and thereafter operatively applying said device to the skin.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-08-30 | 1992-02-29 | 1992-08-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-08-30 | 1996-02-29 | 1996-08-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-08-30 | 2000-02-29 | 2000-08-30 | $7700.00 | Window Closed / Lapsed |